Intellia Therapeutics initiated with an Outperform at Evercore ISI. Evercore ISI analyst Ravi Mehrotra initiated Intellia Therapeutics with an Outperform rating and a price targets of $22. The analyst says the company’s NTLA-1001 is a “well positioned clinical program” in Transthyretin amyloidosis treatment, anticipating a “significant uptake over several antisense oligonucleotides pipeline programs”.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.